JP2023552838A5 - - Google Patents
Info
- Publication number
- JP2023552838A5 JP2023552838A5 JP2023535016A JP2023535016A JP2023552838A5 JP 2023552838 A5 JP2023552838 A5 JP 2023552838A5 JP 2023535016 A JP2023535016 A JP 2023535016A JP 2023535016 A JP2023535016 A JP 2023535016A JP 2023552838 A5 JP2023552838 A5 JP 2023552838A5
- Authority
- JP
- Japan
- Prior art keywords
- carboxamide
- indazole
- methoxy
- cyclohexyl
- pyrazolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063199160P | 2020-12-10 | 2020-12-10 | |
| US63/199,160 | 2020-12-10 | ||
| PCT/EP2021/084916 WO2022122876A1 (en) | 2020-12-10 | 2021-12-09 | N-(imidazo[1,2-b]pyridazin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide and n-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide derivatives as irak4 inhibitors for the treatment of asthma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023552838A JP2023552838A (ja) | 2023-12-19 |
| JP2023552838A5 true JP2023552838A5 (cg-RX-API-DMAC7.html) | 2024-07-26 |
| JP7749015B2 JP7749015B2 (ja) | 2025-10-03 |
Family
ID=79230946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023535016A Active JP7749015B2 (ja) | 2020-12-10 | 2021-12-09 | 喘息の治療のためのirak4阻害剤としてのn-(イミダゾ[1,2-b]ピリダジン-3-イル)-1-シクロヘキシル-2h-インダゾール-5-カルボキサミド及びn-(ピラゾロ[1,5-a]ピリミジン-3-イル)-1-シクロヘキシル-2h-インダゾール-5-カルボキサミド誘導体 |
Country Status (33)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023152349A1 (en) * | 2022-02-14 | 2023-08-17 | Astrazeneca Ab | Irak4 inhibitors |
| US20250326757A1 (en) * | 2022-05-26 | 2025-10-23 | Astrazeneca Ab | Solid forms of heterocyclylamides as irak4 inhibitors |
| US20240374588A1 (en) | 2023-04-07 | 2024-11-14 | Astrazeneca Ab | Irak4 protacs |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5985473B2 (ja) | 2010-07-13 | 2016-09-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | IRAK4モジュレーターとしてのピラゾロ[1,5a]ピリミジン及びチエノ[3,2b]ピリミジン誘導体 |
| HUE029617T2 (en) | 2010-12-20 | 2017-03-28 | Merck Serono Sa | Indazolyl triazole derivatives as IRAK inhibitors |
| BG111378A (bg) * | 2013-01-14 | 2015-01-30 | Николай Цветков | Субституирани индазолови производни като in-vitro mao-b инхибитори |
| RU2665554C2 (ru) * | 2013-03-15 | 2018-08-31 | Байомарин Фармасьютикал Инк. | Ингибиторы hdac |
| HK1231480A1 (zh) | 2014-01-10 | 2017-12-22 | Aurigene Discovery Technologies Limited | 作为irak4抑制剂的吲唑化合物 |
| PL3536685T3 (pl) | 2014-04-04 | 2022-05-16 | Pfizer Inc. | Bicykliczne skondensowane związki heteroarylowe lub arylowe i ich zastosowanie jako inhibitory IRAK4 |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| WO2016174183A1 (en) | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
| CA2992406A1 (en) | 2015-07-15 | 2017-01-19 | Aurigene Discovery Technologies Limited | Indazole and azaindazole compounds as irak-4 inhibitors |
| EP3322409A4 (en) | 2015-07-15 | 2019-07-24 | Aurigene Discovery Technologies Limited | SUBSTITUTED AZA COMPOUNDS AS IRAQ-4 INHIBITORS |
| CN105503863A (zh) * | 2015-12-11 | 2016-04-20 | 南京华威医药科技开发有限公司 | 新型抗肿瘤化合物 |
| EP3394066A2 (en) | 2015-12-22 | 2018-10-31 | H. Hoffnabb-La Roche Ag | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS |
| US10435396B2 (en) | 2016-03-03 | 2019-10-08 | Bayer Pharma Aktiegesellschaft | 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs |
| US10059708B2 (en) | 2016-04-26 | 2018-08-28 | Northwestern University | Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r) |
| WO2017207386A1 (de) | 2016-06-01 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Verwendung von 2-substituierten indazolen zur behandlung und prophylaxe von autoimmunerkrankungen |
| JP2020524692A (ja) | 2017-06-21 | 2020-08-20 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Irak4調節因子としてのベンゾフラン |
| CN110785418A (zh) | 2017-06-21 | 2020-02-11 | 豪夫迈·罗氏有限公司 | 作为irak4调节剂的异二氢吲哚酮衍生物 |
| KR20220027196A (ko) | 2019-06-27 | 2022-03-07 | 바이오젠 엠에이 인코포레이티드 | 이미다조[1,2-a]피리디닐 유도체 및 질병의 치료에서 이것들의 용도 |
| CN114585609B (zh) | 2019-06-27 | 2024-07-30 | 比奥根Ma公司 | 2h-吲唑衍生物及其在疾病治疗中的用途 |
-
2021
- 2021-12-01 US US17/457,249 patent/US11866405B2/en active Active
- 2021-12-09 SI SI202130206T patent/SI4259632T1/sl unknown
- 2021-12-09 AU AU2021395816A patent/AU2021395816B2/en active Active
- 2021-12-09 DK DK21836097.2T patent/DK4259632T3/da active
- 2021-12-09 UA UAA202303173A patent/UA130417C2/uk unknown
- 2021-12-09 MX MX2023006816A patent/MX2023006816A/es unknown
- 2021-12-09 JP JP2023535016A patent/JP7749015B2/ja active Active
- 2021-12-09 HU HUE21836097A patent/HUE068584T2/hu unknown
- 2021-12-09 CR CR20230264A patent/CR20230264A/es unknown
- 2021-12-09 SM SM20240417T patent/SMT202400417T1/it unknown
- 2021-12-09 FI FIEP21836097.2T patent/FI4259632T3/fi active
- 2021-12-09 HR HRP20241312TT patent/HRP20241312T1/hr unknown
- 2021-12-09 RS RS20241183A patent/RS66095B1/sr unknown
- 2021-12-09 LT LTEPPCT/EP2021/084916T patent/LT4259632T/lt unknown
- 2021-12-09 CN CN202180082181.5A patent/CN116583285B/zh active Active
- 2021-12-09 PE PE2023001857A patent/PE20240684A1/es unknown
- 2021-12-09 PL PL21836097.2T patent/PL4259632T3/pl unknown
- 2021-12-09 ES ES21836097T patent/ES2989489T3/es active Active
- 2021-12-09 MA MA62535A patent/MA62535B1/fr unknown
- 2021-12-09 WO PCT/EP2021/084916 patent/WO2022122876A1/en not_active Ceased
- 2021-12-09 EP EP21836097.2A patent/EP4259632B1/en active Active
- 2021-12-09 KR KR1020237023107A patent/KR20230118153A/ko active Pending
- 2021-12-09 PT PT218360972T patent/PT4259632T/pt unknown
- 2021-12-09 CA CA3203569A patent/CA3203569A1/en active Pending
- 2021-12-09 TW TW110145977A patent/TWI902994B/zh active
- 2021-12-10 AR ARP210103432A patent/AR124303A1/es unknown
- 2021-12-10 UY UY0001039561A patent/UY39561A/es unknown
-
2023
- 2023-05-31 IL IL303356A patent/IL303356B2/en unknown
- 2023-06-08 CL CL2023001662A patent/CL2023001662A1/es unknown
- 2023-06-09 CO CONC2023/0007624A patent/CO2023007624A2/es unknown
- 2023-06-09 DO DO2023000119A patent/DOP2023000119A/es unknown
- 2023-07-05 EC ECSENADI202350553A patent/ECSP23050553A/es unknown
- 2023-07-05 ZA ZA2023/06848A patent/ZA202306848B/en unknown
- 2023-11-02 US US18/500,155 patent/US12448385B2/en active Active
-
2025
- 2025-09-29 US US19/343,252 patent/US20260092069A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6862495B2 (ja) | Jak及びpi3k阻害剤併用によるb細胞悪性腫瘍の処置 | |
| JP7398391B2 (ja) | N-[4-オキソ-2,3-ジヒドロ-1,5-ベンズオキサゼピン-3-イル]-5,6-ジヒドロ-4H-ピロロ[1,2-b]ピラゾール-2-カルボキサミド誘導体及び例えば過敏性腸症候群(IBS)を処置するためのRIP1キナーゼ阻害剤としての関連化合物 | |
| TWI836679B (zh) | 化合物、組合物及方法 | |
| TW202308999A (zh) | 作為nav1.8抑制劑之環烷基3—側氧基哌𠯤甲醯胺及環雜烷基3—側氧基哌𠯤甲醯胺 | |
| JP7244504B2 (ja) | PI3K-γ阻害剤としての三級ヒドロキシ基で置換された縮合イミダゾール誘導体 | |
| JP2020532506A5 (cg-RX-API-DMAC7.html) | ||
| EP3675847B1 (en) | Spirocycle compounds and methods of making and using same | |
| JP2010513283A (ja) | 新規なオキサジアゾール化合物 | |
| JP2005516067A5 (cg-RX-API-DMAC7.html) | ||
| JP6482545B2 (ja) | シクロペンチルベンズアミド誘導体及びそれらの精神障害及び認知障害の治療への使用 | |
| JP2012524053A5 (cg-RX-API-DMAC7.html) | ||
| CA2472149A1 (en) | New fluorenecarboxylic acid esters, process for the manufacture thereof and use thereof as medicaments | |
| JP7661361B2 (ja) | Il-17のモジュレーターとしてのイミダゾピリミジン | |
| CZ285479B6 (cs) | Piperidinové deriváty, způsob jejich výroby a farmaceutické prostředky s jejich obsahem | |
| JP2014528433A5 (cg-RX-API-DMAC7.html) | ||
| JP2014508129A (ja) | マルチプルapiローディングプロドラッグ | |
| JP2009542613A5 (cg-RX-API-DMAC7.html) | ||
| JP2010513532A (ja) | スフィンゴシン−1−ホスフェート受容体作働薬および拮抗薬化合物 | |
| JP2009538910A5 (cg-RX-API-DMAC7.html) | ||
| JP2023533203A5 (cg-RX-API-DMAC7.html) | ||
| JP2005525322A5 (cg-RX-API-DMAC7.html) | ||
| JP2013533868A (ja) | タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用 | |
| RS65308B1 (sr) | Biciklična ketonska jedinjenja i postupci za njihovu upotrebu | |
| JP2024536863A (ja) | イミダゾピリダジンil-17阻害剤化合物 | |
| EP0614363A1 (en) | Quinolone derivatives |